@article {SimioniS37.005作者= {Samanta Simioni和马提亚Cavassini和M {\ ' e}拉妮米歇尔和Jean玛丽Annoni和凯蒂·伊格莱西亚斯和艾琳Rimbault亚伯拉罕和亚历山德拉Calmy和支持Giacobini伯纳德Hirschel Renaud Du Pasquier}, title ={卡巴拉汀治疗艾滋病毒相关的神经认知障碍:一项随机,双盲,安慰剂对照,交叉试验研究(S37.005)},体积={78}={1}补充数量,页面= {S37.005——S37.005} ={2012},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:确定卡巴拉汀的安全性和有效性,胆碱酯酶抑制剂,在艾滋病毒相关神经认知障碍(手)。首页背景的流行的手仍然很高,尽管抗逆转录病毒治疗。神经保护药物可以缓解的手。设计/方法:第二,随机,双盲,安慰剂对照,交叉研究的17个HIV阳性患者的手(12人,54.7 {\ textpm} 9.6 y, 660 {\ textpm} 218.2 CD4 +,探测不到艾滋病病毒载量在血浆和CSF,不损伤大脑MRI)。参与者被随机分配接受卡巴拉汀口服(5个月)其次是安慰剂(5个月)后六周冲洗,或安慰剂卡巴拉汀紧随其后。卡巴拉汀逐步增加到12毫克/天。四个研究访问包括神经心理学考试。端点是{\ textquoteright}年代老年痴呆症评估Scale-Cognitive次生氧化皮(ADAS-Cog), 8认知措施的关注/信息处理速度、工作记忆、执行功能和生活质量(MOS-HIV)。之间的区别开始/结束值每五个月的研究期间被用作为每个主体相结合的结果。这一结果,方差分析重复措施(治疗中的效果,手臂之间的因素)计算寻找治疗效果。结果:卡巴拉汀诱导轻/中度9例不良事件消失后轻微的减少剂量(10.3意味着剂量研究结束:{\ textpm} 2.7毫克)。 Four patients withdraw because of severe nausea, nightmares/anxiety and allergic reactions. Attention/processing speed improved on drug (Trail Making Test-A: F(1,13)=5.57, p=0.03). Executive functioning also improved but without reaching statistical significance (CANTAB Spatial Working Memory [strategy]: F(1,13)=3.94, p=0.07). Perceived cognitive functioning (MOS-HIV) showed a trend towards improvement on drug (F[1,13]=2.71, p=0.12). There was no change on the ADAS-Cog.Conclusions: In small trials, drug effects need to be very large to reach statistical significance. This pilot study suggests that rivastigmine in aviremic HAND+ patients may improve typically affected cognitive functions, i.e. information processing speed and executive functioning. A larger trial with the better tolerated trans-cutaneous form of rivastigmine is warranted.Supported by: A grant from the Swiss HIV Cohort Study, a 25{\textquoteright}000.-CHF prize awarded by Abbott to this project and a 15{\textquoteright}000.- CHF unrestricted grant from Novartis.Disclosure: Dr. Simioni has received personal compensation for activities with Gilead and Boehringer Ingelheim as a speaker. Dr. Cavassini has nothing to disclose. Dr. Michel has nothing to disclose. Dr. Annoni has nothing to disclose. Dr. Iglesias has nothing to disclose. Dr. Rimbault Abraham has nothing to disclose. Dr. Calmy has nothing to disclose. Dr. Giacobini has nothing to disclose. Dr. Hirschel has nothing to disclose. Dr. Du Pasquier has received personal compensation for activities with Merck Serono, Biogen Idec, Abbott, and ViiV.Wednesday, April 25 2012, 16:00 pm-17:30 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/78/1_Supplement/S37.005}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }